Oncotarget

Advance Online Publications

January 1, 2021

Dear Authors,

The articles in Advanced Publications have been copyedited and incorporate the authors' final corrections. Please cite the articles using the format: authors, title, journal, year, DOI.

Please note: Advance online publications scheduled to be included in an upcoming issue may not be available during pagination. If your article is currently not available for viewing, please check back after 12:00 PM Eastern Time.

With all respect,
Oncotarget team


Editorial

Fibrocytes in primary myelofibrosis

Fibrocytes in primary myelofibrosis

https://doi.org/10.18632/oncotarget.27971

Kazuya Shimoda, Yoshinori Ozono,  and Kotaro Shide
PDF  |  How to cite  |  Order a Reprint

Javelin Head Neck 100: Should we combine immunotherapy with radiation therapy?

Javelin Head Neck 100: Should we combine immunotherapy with radiation therapy?

https://doi.org/10.18632/oncotarget.27987

Yao Yu, Kaveh Zakeri,  and Nancy Lee
PDF  |  How to cite  |  Order a Reprint

Future directions for immunotherapy in meningioma treatment

Future directions for immunotherapy in meningioma treatment

https://doi.org/10.18632/oncotarget.27994

John W. Rutland, Jonathan T. Dullea,  and Raj K. Shrivastava
PDF  |  How to cite  |  Order a Reprint

Interferon-γ/IRF-1 pathway regulatory mechanisms of PD-L1 expression and relevance for immune checkpoint blockade in hepatocellular carcinoma (HCC)

Interferon-γ/IRF-1 pathway regulatory mechanisms of PD-L1 expression and relevance for immune checkpoint blockade in hepatocellular carcinoma (HCC)

https://doi.org/10.18632/oncotarget.27995

Yihe Yan, Leting Zheng, Qiang Du,  and David A. Geller
PDF  |  How to cite  |  Order a Reprint

Results from a randomized trial combining trastuzumab with a peptide vaccine suggest a role for HER2-targeted therapy in triple-negative breast cancer

Results from a randomized trial combining trastuzumab with a peptide vaccine suggest a role for HER2-targeted therapy in triple-negative breast cancer

https://doi.org/10.18632/oncotarget.27998

Anne E. O’Shea, Guy T. Clifton,  and George E. Peoples
PDF  |  How to cite  |  Order a Reprint

Undetected Barrett’s esophagus: how do we improve early detection?

Undetected Barrett’s esophagus: how do we improve early detection?

https://doi.org/10.18632/oncotarget.28005

Holli A. Loomans-Kropp,  and Ellen Richmond
PDF  |  How to cite  |  Order a Reprint

Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer

Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer

https://doi.org/10.18632/oncotarget.28007

Sasagu Kurozumi, Ayaka Katayama, Ken Shirabe, Jun Horiguchi,  and Emad A. Rakha
PDF  |  How to cite  |  Order a Reprint

Delivering albumin-bound paclitaxel across the blood-brain barrier for gliomas

Delivering albumin-bound paclitaxel across the blood-brain barrier for gliomas

https://doi.org/10.18632/oncotarget.28018

Andrew Gould, Daniel Zhang, Víctor A. Arrieta, Roger Stupp,  and Adam M. Sonabend
PDF  |  How to cite  |  Order a Reprint

Control of the Mdm2-p53 signal loop by β-arrestin 2: the ins and outs

Control of the Mdm2-p53 signal loop by β-arrestin 2: the ins and outs

https://doi.org/10.18632/oncotarget.28065

Elodie Blondel-Tepaz, Hervé Enslen,  and Mark G.H. Scott
PDF  |  How to cite  |  Order a Reprint

Research Perspectives

Ras-p53 genomic cooperativity as a model to investigate mechanisms of innate immune regulation in gastrointestinal cancers

Ras-p53 genomic cooperativity as a model to investigate mechanisms of innate immune regulation in gastrointestinal cancers

https://doi.org/10.18632/oncotarget.27983

Austin R. Dosch, Walid K. Chatila, Yuguang Ban, Anna Bianchi, Nilesh U. Deshpande, Iago De Castro Silva, Nipun B. Merchant,  and Jashodeep Datta
Abstract  |  PDF  |  Full Text  |  How to cite  |  Order a Reprint

Neddylation and anti-tumor immunity

Neddylation and anti-tumor immunity

https://doi.org/10.18632/oncotarget.28019

Xiaoguang Wang, Scott Best,  and Alexey V. Danilov
Abstract  |  PDF  |  Full Text  |  How to cite  |  Order a Reprint

Hepatitis B x antigen (HBx) is an important therapeutic target in the pathogenesis of hepatocellular carcinoma

Hepatitis B x antigen (HBx) is an important therapeutic target in the pathogenesis of hepatocellular carcinoma

https://doi.org/10.18632/oncotarget.28077

Arvin Medhat, Alla Arzumanyan,  and Mark A. Feitelson
Abstract  |  PDF  |  Full Text  |  How to cite  |  Order a Reprint

Recent Research Papers

Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma

Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma

https://doi.org/10.18632/oncotarget.28060

Ricardo Paz-Fumagalli, Jacob Core, Carlos Padula, Seyed Montazeri, John McKinney, Gregory Frey, Zlatko Devcic, Andrew Lewis, Charles Ritchie, Kabir Mody, Sunil Krishnan,  and Beau Toskich
Abstract  |  PDF  |  Full Text  |  How to cite  |  Order a Reprint

NEDD8-activating enzyme inhibition induces cell cycle arrest and anaphase catastrophe in malignant T-cells

NEDD8-activating enzyme inhibition induces cell cycle arrest and anaphase catastrophe in malignant T-cells

https://doi.org/10.18632/oncotarget.28063

Adam S. Kittai, Olga V. Danilova, Vi Lam, Tingting Liu, Nur Bruss, Scott Best, Guang Fan,  and Alexey V. Danilov
Abstract  |  PDF  |  Full Text  |  How to cite  |  Order a Reprint

Trends in oligomannosylation and α1,2-mannosidase expression in human cancers

Trends in oligomannosylation and α1,2-mannosidase expression in human cancers

https://doi.org/10.18632/oncotarget.28064

Sayantani Chatterjee, Julian Ugonotti, Ling Y. Lee, Arun Everest-Dass, Rebeca Kawahara,  and Morten Thaysen-Andersen
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Order a Reprint

Low tumour-infiltrating lymphocyte density in primary and recurrent glioblastoma

Low tumour-infiltrating lymphocyte density in primary and recurrent glioblastoma

https://doi.org/10.18632/oncotarget.28069

Kelsey Maddison, Moira C. Graves, Nikola A. Bowden, Michael Fay, Ricardo E. Vilain, Sam Faulkner,  and Paul A. Tooney
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Order a Reprint

Association of four genetic variants with colorectal cancer in Kazakhstan population

Association of four genetic variants with colorectal cancer in Kazakhstan population

https://doi.org/10.18632/oncotarget.28070

Yevgeniya Kolesnikova, Dmitriy Babenko, Irina Kadyrova, Svetlana Kolesnichenko, Lyudmila Akhmaltdinova, Ilya Korshukov, Naylya Kabildina, Valentina Sirota, Vera Zhumaliyeva, Dana Taizhanova, Dmitriy Vazenmiller,  and Anar Turmukhambetova
Abstract  |  PDF  |  Full Text  |  How to cite  |  Order a Reprint

TP53 mutations determined by targeted NGS in breast cancer: a case-control study

TP53 mutations determined by targeted NGS in breast cancer: a case-control study

https://doi.org/10.18632/oncotarget.28071

Angeliki Andrikopoulou, Evangelos Terpos, Spyridoula Chatzinikolaou, Kleoniki Apostolidou, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Meletios-Athanasios Dimopoulos,  and Flora Zagouri
Abstract  |  PDF  |  Full Text  |  How to cite  |  Order a Reprint

Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells

Pan-drug and drug-specific mechanisms of 5-FU, irinotecan (CPT-11), oxaliplatin, and cisplatin identified by comparison of transcriptomic and cytokine responses of colorectal cancer cells

https://doi.org/10.18632/oncotarget.28075

Lindsey Carlsen, Christoph Schorl, Kelsey Huntington, Liz Hernandez-Borrero, Aakash Jhaveri, Shengliang Zhang, Lanlan Zhou,  and Wafik S. El-Deiry
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Order a Reprint

The experiences and needs of Australian medical oncologists in integrating comprehensive genomic profiling into clinical care: a nation-wide survey

The experiences and needs of Australian medical oncologists in integrating comprehensive genomic profiling into clinical care: a nation-wide survey

https://doi.org/10.18632/oncotarget.28076

Subotheni Thavaneswaran, Mandy Ballinger, Phyllis Butow, Bettina Meiser, David Goldstein, Frank Lin, Christine Napier, David Thomas,  and Megan Best
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Order a Reprint

Luminescence complementation technology for the identification of MYC:TRRAP inhibitors

Luminescence complementation technology for the identification of MYC:TRRAP inhibitors

https://doi.org/10.18632/oncotarget.28078

Edmond J. Feris, John W. Hinds,  and Michael D. Cole
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Order a Reprint

A high-throughput customized cytokinome screen of colon cancer cell responses to small-molecule oncology drugs

A high-throughput customized cytokinome screen of colon cancer cell responses to small-molecule oncology drugs

https://doi.org/10.18632/oncotarget.28079

Kelsey E. Huntington, Anna Louie, Lanlan Zhou,  and Wafik S. El-Deiry
Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite  |  Order a Reprint


Copyright © 2021 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC